CAR-T FOR B-CELL ALL IN CHINA:
ELIGIBILITY, OUTCOMES & ACCESS
B-cell ALL is the indication where CAR-T produces its highest response rates — 70–90% complete remission in chemotherapy-resistant disease. China's centres deliver this at a fraction of Western cost.
analyticsAt a Glance
- check_circleCD19-directed CAR-T achieves 70–90% complete remission in r/r B-ALL — the highest response rates of any CAR-T indication
- check_circleCAR-T is used as a bridge to allogeneic transplant in eligible patients — consolidation prevents relapse in long-term responders
- check_circleChina's NMPA has approved CD19-directed CAR-T for paediatric and adult r/r B-ALL
- check_circlePKUPH Beijing and Ruijin Hospital Shanghai are China's leading B-ALL CAR-T centres — accessible through CancerFax
Why CAR-T Is Particularly Powerful in B-Cell ALL
B-cell ALL presents a uniquely favourable biology for CD19-directed CAR-T — virtually all B-ALL expresses CD19 uniformly and at high density, providing an abundant target for CAR-T activity. The immune system's ability to access leukaemia cells in the blood and bone marrow (as opposed to a solid tumour mass) also facilitates effective T cell engagement. The result is complete remission rates of 70–90% in patients who have failed two or more prior lines of chemotherapy — including those who have failed prior allogeneic transplantation.
“In B-cell ALL, CAR-T does not just improve outcomes — it rescues patients whose leukaemia has become resistant to everything else.”
Paediatric ALL: The Original CAR-T Indication
Tisagenlecleucel (Kymriah) received the world's first CAR-T approval in August 2017 — specifically for paediatric and young adult r/r B-cell ALL. The pivotal ELIANA trial demonstrated 81% overall remission rate with 60% complete remission and 12-month EFS of 50% — transformative in a disease where prior salvage options had failed.
Adult ALL: Growing Evidence Base
Adult B-ALL has historically had worse outcomes than paediatric ALL with chemotherapy and transplant. CAR-T studies in adults with r/r B-ALL show CR rates of 60–80% — comparable to paediatric data — with the majority using CAR-T as a bridge to allogeneic transplantation rather than as definitive therapy.
B-ALL CAR-T Efficacy: Key Clinical Numbers
Response rate benchmarks from pivotal paediatric and adult B-ALL CAR-T trials and Chinese centre published data.
- 81%Overall remission rate in paediatric r/r B-ALL — ELIANA trial (tisagenlecleucel)The ELIANA pivotal trial: 81% ORR, 60% CR in children and young adults with r/r B-ALL after ≥2 prior lines, prior transplant, or primary refractory disease. 12-month EFS 50% — the data that established paediatric ALL as the premier CAR-T indication.
- 85–90%MRD-negative CR rate in Chinese academic ALL CAR-T seriesPublished series from PKUPH and Ruijin Hospital demonstrate MRD-negative complete remission rates of 85–90% in Chinese paediatric and adult B-ALL — consistent with Western pivotal trial data.
- 50–60%2-year overall survival in r/r B-ALL patients who achieve CR and proceed to allo-SCT after CAR-TPatients who achieve MRD-negative CR with CAR-T and then consolidate with allogeneic stem cell transplant achieve 2-year OS of 50–60% — substantially better than the historical 10–15% OS for chemotherapy-resistant ALL.
B-ALL CAR-T Eligibility: Criteria and Considerations
Eligibility for CD19-directed CAR-T in B-cell ALL is broadly defined — the main considerations are B-cell lineage confirmation, CD19 expression, and the role of subsequent transplant.
| Eligibility Criterion | Standard Requirement | Clinical Notes |
|---|---|---|
| Diagnosis | B-cell precursor ALL (B-ALL) — not T-ALL or AML | Cell lineage confirmation by flow cytometry and immunophenotyping essential; T-ALL does not express CD19 |
| CD19 expression | CD19+ by flow cytometry from bone marrow aspirate or peripheral blood blasts | CD19 expression should be confirmed from the most recent sample; prior rituximab does not affect CD19 |
| Age | Paediatric: ≥1 year (weight-based dosing); Adult: no upper age limit — fitness assessment determines eligibility | Children under 1 year require individual assessment; adults into their 60s–70s have been treated at Chinese centres |
| Prior treatment lines | ≥2 prior chemotherapy lines; OR primary refractory; OR relapse post-allo-SCT | No specific minimum prior line in Chinese protocols — eligibility is based on r/r status, not line count alone |
| Post-allo-SCT relapse | Eligible — CAR-T is particularly valuable in post-transplant relapse where further chemotherapy has limited efficacy | Must be off immunosuppression and no active GvHD; graft-versus-host disease risk with CAR-T from original donor cells |
| CNS ALL | Variable — active CNS disease is excluded from most standard protocols; CNS2 may be permissible with IT prophylaxis | CNS disease reduces CAR-T efficacy; intrathecal prophylaxis should be continued |
| Philadelphia chromosome (Ph+) ALL | Eligible — Ph+ ALL qualifies for CAR-T; TKI (ponatinib) combined with or following CAR-T being studied | Ph+ does not exclude CAR-T; TKI should be continued as maintenance post-CAR-T in Ph+ ALL |
The B-ALL CAR-T Treatment Pathway: From Infusion to Transplant
B-ALL CAR-T is typically used as a bridge to allogeneic transplantation rather than as a standalone curative therapy — understanding this sequence is essential for treatment planning.
- 1
CAR-T Infusion to Achieve MRD-Negative CR
CD19-directed CAR-T is infused following lymphodepletion (fludarabine + cyclophosphamide). The goal is MRD-negative complete remission — assessed by flow cytometry (sensitivity 10⁻⁴) or PCR (sensitivity 10⁻⁵ or 10⁻⁶) at day 28 and day 60 post-infusion.
- 2
Response Assessment at Day 28 and Day 60
Bone marrow aspirate with MRD assessment at day 28 post-infusion defines early response. MRD-negative status at day 28 strongly predicts durable response and transplant outcome. Persistent MRD-positive CR at day 28 warrants additional assessment and discussion of transplant timing.
- 3
Donor Search and Transplant Planning
For eligible patients achieving MRD-negative CR, allogeneic stem cell transplant should be planned within 3–4 months — before CAR-T cell exhaustion and potential relapse. Donor search begins at the same time as CAR-T manufacturing. China's Peking Protocol haploidentical transplant enables transplant even when no matched donor exists.
- 4
Allogeneic SCT (Consolidation for Most Patients)
Current evidence supports allo-SCT after CAR-T-induced MRD-negative CR for most adult patients with r/r B-ALL — transplant significantly reduces relapse rates compared to CAR-T alone. Paediatric patients may achieve sustained remission without transplant in some low-risk scenarios — discussed in MDT.
- 5
Patients Who Cannot Proceed to Transplant
For patients who are transplant-ineligible, CAR-T without transplant consolidation is an option — some long-term remissions occur, though relapse rates are higher than in transplanted patients. Ongoing maintenance strategies (ponatinib in Ph+ ALL, CIBMTR registry data) are being studied.
Paediatric vs Adult B-ALL: CAR-T Differences That Matter
B-cell ALL CAR-T is approved and available for both children and adults — but there are important clinical and logistical differences between the two populations.
Paediatric B-ALL (Age <18 / Young Adult)
- Higher CR rates and better T cell fitnessChildren have higher overall CAR-T CR rates (80–90%) than adults (60–75%) — reflecting better baseline T cell quality, less prior treatment-related immunosuppression, and more robust in vivo T cell expansion.
- Lower CRS and ICANS severity overallPaediatric patients generally experience less severe CRS than adults — though any grade cytokine release should be monitored closely. Neurological monitoring is especially important in children due to ICANS risk.
- Tisagenlecleucel (Kymriah) — the paediatric-licensed product globallyTisagenlecleucel is specifically approved for children and young adults (≤25 years) with r/r B-ALL in the USA and Europe. In China, equivalent products with paediatric approval are available. Chinese centres including PKUPH have the world's largest paediatric ALL CAR-T case experience.
Adult B-ALL (Age ≥18)
- Lower CR rates — but still better than any alternativeAdult B-ALL has lower baseline T cell fitness due to more prior treatment. CR rates of 60–75% in heavily pre-treated adults still far exceed what salvage chemotherapy achieves (10–20%).
- Transplant consolidation is more consistently indicatedFor adult patients achieving CR with CAR-T, allo-SCT consolidation is strongly recommended — the relapse rate without transplant is significantly higher in adults than in children.
- Ph+ ALL: TKI continuation is standard alongside CAR-TPhiladelphia chromosome-positive ALL (BCR::ABL1) requires ongoing TKI therapy (ponatinib preferred for resistance mutations) alongside or following CAR-T — a specific consideration more relevant in adult ALL where Ph+ incidence is higher (25–30% vs 3–5% in paediatrics).
Frequently Asked Questions
Common questions from B-ALL patients and families considering CAR-T therapy in China.
About B-Cell ALL CAR-T in China
My child has relapsed ALL after allogeneic transplant — is CAR-T still an option?
Yes — post-allo-SCT relapse is one of the strongest indications for CAR-T in B-ALL. Conventional chemotherapy has very limited efficacy in this scenario, and the risk of additional treatment-related mortality is high. CAR-T achieves MRD-negative CR in 70–80% of post-transplant relapse patients. In China, PKUPH specifically has extensive experience with this scenario — and their haploidentical transplant programme enables a second transplant if needed after CAR-T-induced remission.
Does CAR-T cure B-cell ALL?
Long-term cure is possible but depends heavily on subsequent allogeneic transplant. Patients who achieve MRD-negative CR with CAR-T and consolidate with allo-SCT achieve 2-year OS of 50–60% and some fraction appear durably cured. Without transplant consolidation, relapse rates are higher. The word 'cure' is used cautiously in r/r ALL given the prior treatment history — but CAR-T + transplant offers the best available chance at long-term disease control in this population.
How does CAR-T for ALL differ from CAR-T for lymphoma (DLBCL)?
Key differences: ALL CAR-T produces higher CR rates (80–90% vs 40–60% for DLBCL) but is typically used as a bridge to allo-SCT rather than as definitive therapy — long-term remission without transplant is less common in ALL. ALL CAR-T may cause more pronounced B cell aplasia and hypogammaglobulinaemia due to deeper and more sustained B cell depletion. The monitoring schedule and post-infusion management are similar between indications.
What centres in China perform B-ALL CAR-T and how do I access them?
PKUPH (Peking University People's Hospital, Beijing) is China's leading B-ALL CAR-T centre — the same institution that pioneered haploidentical transplantation and has among Asia's largest paediatric ALL case volumes. Ruijin Hospital (Shanghai Jiao Tong University) is the other principal centre. Both are accessible through CancerFax — we manage the full process from eligibility review to discharge and follow-up coordination with your home haematologist.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T guides — from target biology and approved products to DLBCL-specific pages.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access CAR-T for B-Cell ALL in China Through CancerFax
CancerFax reviews your B-ALL treatment history, MRD status, molecular profile, and transplant candidacy to assess CAR-T eligibility — and coordinates the complete access pathway at PKUPH, Ruijin Hospital, or other leading Chinese B-ALL CAR-T centres.
This content is for informational purposes only. CAR-T eligibility must be assessed by a qualified haematologist at a centre experienced in B-ALL management.